Kolexia
Oberic Lucie Oncologie médicale
Oberic Lucie
Oncologie médicale
Oncopole Toulouse
Toulouse, France
212 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome à cellules du manteau Lymphome B Lymphome B diffus à grandes cellules Leucémie chronique lymphocytaire à cellules B Maladie de Hodgkin Récidive tumorale locale Lymphome malin non hodgkinien Leucémies

Collaborateurs

Voir plus
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Thieblemont Catherine
Thieblemont Catherine
Hôpital Saint-Louis, Paris, France
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France

Industries

Voir plus
Janssen
24 collaboration(s)
Dernière en 2023
Roche
20 collaboration(s)
Dernière en 2023
Gilead
13 collaboration(s)
Dernière en 2023
Abbvie
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
POLARIX: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Essai Clinique (Roche)   15 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient.
Transplantation direct   26 février 2024
Assessment of Seasonality in Eosinophilic Dermatosis of Haematological Malignancy.
Acta dermato-venereologica   19 février 2024
An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma: An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Essai Clinique (Acerta Pharma BV)   19 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   18 décembre 2023
Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials
65th ASH Annual Meeting Abstracts   02 novembre 2023
Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy
65th ASH Annual Meeting Abstracts   02 novembre 2023